Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Hill NL, Mogle J, Bhargava S, Bell TR, Bhang I, Katz M, Sliwinski MJ. Longitudinal relationships among depressive symptoms and three types of memory self-report in cognitively intact older adults. Int Psychogeriatr. 2020 Jun;32(6):719-32. doi: 10.1017/S104161021900084X
Schelfhout J, Jiang Y, Miles L, Merchant S, Graham J. Cost effectiveness of letermovir as cytomegalovirus prophylaxis in in allogeneic hematopoietic stem cell transplant recipients. Poster presented at the 2018 BMT Tandem Meetings; February 2018. Salt Lake City, UT. [abstract] Biol Blood Marrow Transplant. 2018 Mar; 24(3 Supplement):S384. doi: 10.1016/j.bbmt.2017.12.473
Hill NL, McDermott C, Mogle J, Munoz E, DePasquale N, Wion R, Whitaker E. Subjective cognitive impairment and quality of life: a systematic review. Int Psychogeriatr. 2017 Dec;29(12):1965-77.
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988